trial
as of 2026-07-01Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
NCTId NCT00549718
at a glance
Phase 3 · Completed
Enrollment 489 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2010-10
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
489 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-10
Primary completion
2010-10
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Drugs
Indications
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Medical Director, MDStudy Director
Sites
48 total
Little Rock, United StatesCerritos, United StatesCosta Mesa, United StatesGarden Grove, United StatesParamount, United StatesPasadena, United StatesPico Rivera, United StatesSan Diego, United StatesWashington D.C., United StatesBradenton, United StatesNorth Miami, United StatesAtlanta, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
489
Phase
PHASE3
Primary Completion Date
2010-10
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person